文献速递淋巴瘤

CAR-HEMATOTOX评分预测经重度预处理B细胞非霍奇金淋巴瘤患者接受odronextamab治疗的不良结局风险

CAR-HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B-cell non-Hodgkin lymphoma.
PubMed 文献 · Br J Haematol · 2026-10-21

本研究基于ELM-1和ELM-2研究,回顾性评估基线CAR-HEMATOTOX评分对接受CD20×CD3双特异性抗体odronextamab治疗的复发/难治性滤泡性淋巴瘤(FL)或弥漫性大B细胞淋巴瘤(DLBCL)患者的预后价值。结果显示高评分(≥2)患者早期细胞因子释放综合征、严重感染和中性粒细胞恢复延迟发生率数值更高,且无进展生存期和总生存期显著更差。提示该评分可用于识别odronextamab治疗高风险患者。

要点

  • 高CAR-HEMATOTOX评分与odronextamab治疗后更差的无进展生存期和总生存期显著相关。
  • 高评分患者早期严重细胞因子释放综合征、感染和中性粒细胞恢复延迟发生率数值更高。
  • CAR-HEMATOTOX评分或可作为一种简便工具用于风险分层。

核心结论

  • CAR-HEMATOTOX评分可能有助于识别接受odronextamab治疗且临床结局较差风险较高的患者。

研究设计与样本

  • 回顾性分析ELM-1(NCT02290951)和ELM-2(NCT03888105)研究中接受odronextamab治疗的复发/难治性FL或DLBCL患者。
  • 按基线CAR-HEMATOTOX评分分层:低评分(0-1分;FL n=115,DLBCL n=92)和高评分(≥2分;FL n=24,DLBCL n=98)。

主要发现

  • 高评分 vs 低评分患者中,治疗前30天内≥2级细胞因子释放综合征发生率及前90天内≥3级感染和中性粒细胞恢复延迟率数值更高。
  • DLBCL患者中高评分 vs 低评分的中位无进展生存期显著更差:2.6 vs 9.6个月(p<0.0001)。
  • FL患者中高评分 vs 低评分的中位总生存期显著更差:26.5个月 vs 未达到(p=0.030)。
  • DLBCL患者中高评分 vs 低评分的中位总生存期显著更差:4.8 vs 17.2个月(p<0.0001)。

临床怎么用

  • 在启动odronextamab治疗前可计算基线CAR-HEMATOTOX评分以辅助风险分层。
  • 对高评分患者应加强早期细胞因子释放综合征、感染和中性粒细胞恢复的监测。

局限性

  • 本研究为回顾性分析。
  • 样本来自ELM-1和ELM-2两项研究,高评分亚组样本量较小(FL n=24)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The CAR-HEMATOTOX model has been shown to help identify patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) at heightened risk of severe neutropenia, serious infection and worse clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy. We evaluated whether CAR-HEMATOTOX scores had prognostic value in patients with R/R follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) treated with odronextamab (cluster of differentiation [CD]20 × CD3 bispecific antibody) in the ELM-1 (NCT02290951) and ELM-2 (NCT03888105) studies. Patients were retrospectively stratified by baseline CAR-HEMATOTOX score: CAR-HEMATOTOX score low (HTlow [0-1]; FL, n = 115, DLBCL, n = 92) or CAR-HEMATOTOX score high (HThigh [≥2]; FL, n = 24, DLBCL, n = 98). The incidence of grade ≥2 cytokine release syndrome within the first 30 treatment days, and rates of grade ≥3 infection and delayed neutrophil recovery within the first 90 treatment days, were numerically higher in HThigh versus HTlow patients. In patients with HThigh versus HTlow scores, progression-free survival (PFS) was significantly poorer in DLBCL (2.6 vs. 9.6 months [p < 0.0001]), and overall survival (OS) was significantly worse in FL and DLBCL (FL, 26.5 months vs. not reached [p = 0.030]; DLBCL, 4.8 vs. 17.2 months [p < 0.0001]). These results suggest that the CAR-HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Matasar M, Tucker D, Kim TM, et al. CAR-HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B-cell non-Hodgkin lymphoma. Br J Haematol. 2026. PMID: 42906902. doi:10.1111/bjh.70869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。